Form D · Other Health Care

Acuamark Diagnostics, Inc.

New York, NY · CIK 0001685619

Offering snapshot reported Jun 4, 2024 · SEC filing

Reported sold
$4.94M
Offering amount: $12M
Investors reported
20
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
May 22, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 4, 2024Initial$4,941,620No comparison20SEC filing
Apr 6, 2022Initial$11,623,242No comparison41SEC filing
Sep 25, 2019Initial$2,289,501No comparison29SEC filing
Nov 17, 2016Initial$1,478,834No comparison20SEC filing

Offering details

Securities
Equity, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$125K (estimated)
Finders' fees
$84.1K (estimated)
Form D file number
021-515110

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Finalis Securities LLC305908

Source: Form D, filed Jun 4, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Brian Carr Director
Claudio Del Vecchio Director
Cedric Francois Director
Michael Gargano Director
William Gedale Director
Michael Hanbury Director
Howard Johnson Director
Giulia Kennedy Director
Gregory Murdock Director
Bernard Peperstraete Director, Executive
Joseph Smith Director
Vanja Vuletic Director
David Weavil Director

Issuer details

Industry: Other Health Care (See others in industry)

Address:
101 Avenue Of The Americas Floor 13 (C/O Jlabs)
New York, NY, 10020